Healthcare Services

Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Size Outlook and Demand Growth Across 2026–2030

April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The market size for paroxysmal nocturnal hemoglobinuria (pnh) has experienced significant expansion in recent times. It is anticipated to increase from $4.67 billion in 2025 to $5.09 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.1%. This historical development can be ascribed to several factors, including the scarce availability of effective targeted therapies, challenges in diagnosis due to the disease’s rarity, a dependence on supportive care and transfusions, the substantial mortality associated with untreated pnh, and a general lack of awareness among healthcare providers.

The paroxysmal nocturnal hemoglobinuria (pnh) market is projected to experience robust expansion over the coming years, anticipated to reach $7.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.9%. This projected growth is attributable to factors such as the emergence of next-generation complement inhibitors, higher diagnosis rates facilitated by advanced testing, an intensified focus on treating orphan diseases, improved accessibility to specialized hematology centers, and broadened reimbursement coverage for rare disease therapies. Key trends during this period are expected to encompass the increasing uptake of complement inhibitor therapies, greater reliance on flow cytometry for precise diagnosis, the development of long-acting monoclonal antibody treatments, the expansion of specialized rare hematology care initiatives, and enhanced strategies for managing thrombosis and hemolysis complications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12936&type=smp

What Key Drivers Are Influencing The Growth Of The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

The increasing occurrence of blood disorders and bone marrow-related conditions is projected to drive the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market moving forward. Blood disorders refer to medical issues that impact the composition, performance, and creation of blood and its components. Bone marrow-related disorders occur either when the bone marrow fails to produce sufficient red, white, or platelet cells, or when the blood cells generated are damaged or defective. PNH is closely connected to both blood disorders and bone marrow-related disorders because of its effect on blood cell production, immune system function, and the microenvironment of the bone marrow. It is a rare blood disorder associated with bone marrow failure diseases, resulting from a genetic flaw that impairs the function of red blood cells and platelets. For instance, Blood Cancer United, a UK-based nonprofit advocacy group dedicated to raising awareness and support for blood cancer patients, projects that in 2025, roughly 192,070 individuals in the U.S. will be diagnosed with leukemia, lymphoma, or myeloma. Therefore, the rising incidence of blood disorders and bone marrow-related disorders is fueling the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) market.

What Major Segment Divisions Exist Within The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

The paroxysmal nocturnal hemoglobinuria (pnh) market covered in this report is segmented –

1) By Treatment Type: Medications, Bone Marrow Transplantation, Blood Transfusion, Immunosuppressive Therapy, Other Treatment Types

2) By Diagnosis Type: Flow Cytometry, High-Resolution Mass Spectrometry, Other Diagnosis Types

3) By End Use: Hospitals, Clinics, Other End Users

Subsegments:

1) By Medications: Eculizumab, Ravulizumab, Complement Inhibitors, Supportive Care Medications

2) By Bone Marrow Transplantation: Allogeneic Stem Cell Transplantation, Autologous Stem Cell transplantation

3) By Blood Transfusion: Red blood Cell Transfusion, Platelet Transfusion, Fresh Frozen Plasma Transfusion

4) By Immunosuppressive Therapy: Corticosteroids, Azathioprine, Cyclophosphamide, Mycophenolate Mofetil

5) By Other Treatment Types: Supportive Therapies, Management Of Complications

What Major Market Trends Are Driving Changes In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

Major companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) market are concentrating on developing new and innovative drugs and therapies, including injectable C5 inhibitors for the management of paroxysmal nocturnal hemoglobinuria (PNH), to sustain their market position. An injectable C5 inhibitor is a type of monoclonal antibody that works by blocking the complement component C5, thereby reducing inflammation and tissue damage in autoimmune diseases and conditions such as paroxysmal nocturnal hemoglobinuria (PNH). As an illustration, in February 2024, Chugai Pharmaceutical Co., a Japan-based pharmaceutical company, secured priority review approval from China’s National Medical Products Administration (NMPA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). This significant event establishes China as the first country to approve PIASKY, preceding other major markets, which will allow it to engage in National Reimbursement Drug List (NRDL) negotiations within the same year. PNH, being classified as a rare disease, affects an estimated 12,740 individuals in China, indicating considerable market potential.

Which Companies Are Leading Innovation In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc, Novartis AG, Thermo Fisher Scientific Inc, GE Healthcare, Grifols S.A, Genentech Inc, Bioverativ Inc, BioCryst Pharmaceuticals, Hansa Biopharma AB, Apellis Pharmaceuticals Inc, Akari Therapeutics Plc, RA Pharmaceuticals Inc, C5 Therapeutics Inc, Omeros Corporation, Amyndas Pharmaceuticals SA, CANbridge Pharmaceuticals, NovelMed Therapeutics Inc, Annexon Inc, Dianthus Therapeutics, DynamiCure Biotechnology, Kira Pharmaceuticals Ltd, Kyowa Kirin Co Ltd, Swedish Orphan Biovitrum AB, Arrowhead Pharmaceuticals, ReAlta Life Sciences, Q32 Bio, ISU Abxis

Read the full paroxysmal nocturnal hemoglobinuria (pnh) market report here:

https://www.thebusinessresearchcompany.com/report/paroxysmal-nocturnal-hemoglobinuria-pnh-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2025. The regions covered in the paroxysmal nocturnal hemoglobinuria (pnh) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12936&type=smp

Browse Through More Reports Similar to the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market 2026, By The Business Research Company

Neurological Disorder Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Wolff Parkinson White Syndrome Global Market Report

https://www.thebusinessresearchcompany.com/report/wolff-parkinson-white-syndrome-global-market-report

Rare Neurological Disease Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795